NCT00680134View on ClinicalTrials.gov

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Onychomycosis
Interventions
DRUG

AN2690

AN2690 1% Solution, once daily for 180 days

DRUG

AN2690

AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days

Trial Locations (7)

10032

Columbia University Medical Center, New York

35233

University of Alabama at Birmingham, Birmingham

77802

J&S Studies, Bryan

78229

Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC, San Antonio

78759

DermResearch, Inc., Austin

87106

Academic Dermatology Associates, Albuquerque

94143-0517

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00680134 - Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis | Biotech Hunter | Biotech Hunter